Progesterone: Why Route, Dose and Timing Matter

Progesterone physiology, in brief

Progesterone is produced by the corpus luteum after ovulation and, in pregnancy, by the placenta. Its best-known roles are preparing and maintaining the uterine lining for implantation and pregnancy and, outside of pregnancy, balancing the proliferative effect of estrogen on the endometrium. Progesterone receptors are also present in the brain, breast, and other tissues, which is part of why progesterone therapy is associated with effects beyond the reproductive tract, including commonly reported sedative and mood-related effects for some patients.

Progesterone vs. synthetic progestogens/progestins

"Progesterone" and "progestin" are often used loosely, but they are not the same thing. Micronized progesterone is manufactured to be chemically identical to the progesterone the body produces — this is what "bioidentical" refers to here, and it is a statement about molecular structure, not a claim about comparative safety or effectiveness. Synthetic progestogens/progestins (such as medroxyprogesterone acetate or various progestins used in oral contraceptives) are structurally different molecules designed to bind the progesterone receptor, and they can differ from progesterone itself — and from each other — in receptor selectivity, metabolite profile, and side-effect pattern; not all synthetic progestins should be assumed pharmacologically or clinically identical to one another. Much of the large-scale outcome data in menopausal hormone therapy — most notably the Women's Health Initiative (WHI) hormone therapy trials, which studied conjugated equine estrogens (CEE) 0.625 mg/day plus medroxyprogesterone acetate (MPA) 2.5 mg/day in women with a uterus^[1] — used a specific synthetic progestin, not micronized progesterone, which is one reason the two categories should not be assumed to carry identical risk profiles. That distinction cuts both ways: it means micronized progesterone should not be assumed equivalent to a specific progestin, but it likewise does not by itself establish that micronized progesterone is safer or produces better outcomes — that comparison depends on the specific progestin, dose, route and population being compared, and requires its own evidence.

For breast-tissue outcomes specifically, one large French prospective cohort study (the E3N cohort; 80,377 postmenopausal women, mean follow-up 8.1 years) found that estrogen combined with progesterone was not associated with increased breast cancer risk relative to no hormone therapy (relative risk 1.00; 95% CI, 0.83–1.22), while estrogen combined with other synthetic progestins, considered together, was associated with a higher relative risk (1.69; 95% CI, 1.50–1.91).^[6] This is observational cohort evidence from one study population, not a randomized controlled trial — no randomized trial has compared progesterone against specific progestins with breast cancer as a primary outcome — and observational hormone-therapy studies of this kind can be affected by channeling bias (differences in which patients are prescribed which formulation, and why). The Menopause Society's current patient guidance is directionally consistent, noting that among women using combined estrogen-progestogen therapy, breast cancer risk "might be lower" with micronized progesterone used intermittently and started early in menopause^[5] — though that statement bundles progestin choice together with dosing pattern and timing of initiation, and should not be read as isolating progesterone choice alone as the explanation.

Oral micronized progesterone

Oral micronized progesterone is well absorbed but undergoes substantial first-pass hepatic metabolism, producing metabolites — including allopregnanolone, a potent positive modulator of the GABA-A receptor — that interact with GABA-A receptors in the brain. A clinical study using an objective measure of sedation (saccadic eye velocity) found that oral progesterone administration produced measurable sedation, consistent with enhanced GABA-A receptor activity from allopregnanolone.^[2] This is generally understood to be the basis of the sedative effect many patients notice with oral progesterone, which is also why oral progesterone is commonly dosed at bedtime. These pharmacokinetics are best established for FDA-approved oral micronized progesterone; specific absorption and metabolite figures should not be assumed identical for every compounded oral progesterone formulation.

Sublingual and buccal administration

Sublingual and buccal administration allow absorption through the oral mucosa, which can partially bypass first-pass hepatic metabolism; a portion of a sublingual or buccal dose may still be swallowed and processed through the oral/GI route rather than absorbed through the mucosa. This route is generally described as producing a relatively rapid rise in serum progesterone with a shorter duration of peak effect compared with oral dosing, and it is sometimes chosen when a patient does not tolerate the sedative effect of oral dosing well, or when a prescriber wants a different absorption/metabolite profile.

Topical administration

Topical (transdermal) progesterone is absorbed through the skin directly into systemic circulation, avoiding first-pass hepatic metabolism — it is genuinely absorbed, not merely applied to the surface with no systemic effect. The clinically important question, however, is not whether topical progesterone is absorbed, but whether the resulting exposure reliably protects the endometrium in a patient who is also taking systemic estrogen. A 2016 systematic review of the evidence on micronized progesterone and the endometrium concluded that transdermal micronized progesterone does not provide endometrial protection — a different conclusion than the same review reached for oral and vaginal micronized progesterone, which it found could provide protection at specific studied doses and durations.^[3] (The oral and vaginal regimens that review evaluated — for example, oral progesterone 200 mg/day for 12–14 days/month for up to 5 years, or vaginal progesterone 4% gel [45 mg/day] for at least 10 days/month, or 100 mg every other day, for up to 3–5 years — are cited here as examples of what the studies in that review examined, not as an individualized prescribing recommendation.) This is a clinically important, evidence-based limitation specific to the transdermal route. It does not change simply because compounded progesterone creams are commonly used in practice — absorption and proven endometrial protection are two different questions, and the evidence reviewed answers them differently for this specific route.

Vaginal administration

Vaginal progesterone (as a suppository, insert, or compounded preparation) takes advantage of a "first-uterine-pass effect": a foundational pharmacokinetic study found uterine tissue progesterone concentrations more than 10-fold higher after vaginal administration than after systemic administration, despite plasma progesterone levels being more than seven-fold higher in the systemic-administration group^[4] — indicating a direct vaginal-to-uterine transport pathway distinct from ordinary systemic absorption. This tissue-concentration finding is consistent with, though distinct from, clinical evidence that vaginal micronized progesterone at specific studied doses and durations can provide endometrial protection (see "Endometrial protection considerations," below).^[3] This route is well established in specific contexts such as certain fertility protocols and preterm birth prevention, and is also used in some menopausal hormone therapy regimens.

First-pass metabolism and metabolites

The differences above all trace back to one pharmacologic concept: first-pass hepatic metabolism. Oral progesterone passes through the liver before reaching systemic circulation, generating a distinct metabolite profile (including allopregnanolone) at levels that other routes do not reproduce in the same way. Routes that bypass or partially bypass the liver — sublingual, topical, vaginal — change not just the amount of progesterone reaching circulation, but the balance of progesterone to its metabolites. This is a central reason different routes are not simply "the same dose, different delivery."

Endometrial protection considerations

For patients on estrogen therapy who have a uterus, adequate progesterone (or a progestogen) exposure is used to protect the endometrium from unopposed estrogen stimulation, reducing the risk of endometrial hyperplasia and cancer. What counts as "adequate" depends on dose, route, duration, and the estrogen regimen it is paired with — it is not a single number that applies identically across all formulations. As detailed above, current systematic-review evidence indicates that the transdermal route specifically does not reliably provide this protection, in contrast to oral and vaginal micronized progesterone at their studied doses.^[3] The Menopause Society separately cautions that custom-compounded hormone products "may not even contain the prescribed amounts of hormones," and that when progesterone exposure is too low, a patient "is not protected against endometrial (uterine) cancer"^[5] — underscoring that both route selection and compounded-product quality control are part of this clinical picture, not just the nominal dose written on a prescription. This is an area where the choice of route is a clinically meaningful decision, not just a matter of patient preference.

Why a serum level alone may not tell the whole story

A single serum progesterone level reflects a snapshot in time and is affected by the route of administration, how recently the dose was taken, and normal pharmacokinetic variability between individuals. For routes with a short time-to-peak and shorter duration of elevated levels (such as sublingual dosing), a level drawn at the wrong time relative to the last dose may under- or over-represent typical exposure. This is one reason interpretation of a progesterone level should always be done in the context of the specific route, dosing schedule, and timing of the blood draw — not compared against a route-agnostic reference range.

Timing of laboratory testing

Because progesterone pharmacokinetics differ meaningfully by route, the timing of a blood draw relative to the last dose is clinically important, and testing protocols are usually set by the prescriber based on the specific formulation and route in use. Trends over multiple consistently-timed tests are generally more informative than a single isolated value.